Fulgent Genetics (FLGT) Long-Term Investments (2017 - 2026)

Fulgent Genetics has disclosed Long-Term Investments across 10 years of filings, most recently posting $328.3 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $328.3 million, down 33.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $328.3 million (down 33.56% YoY), and the FY2025 annual result was $369.3 million, down 35.26% from the prior year.
• Long-Term Investments came in at $328.3 million for Q1 2026 at Fulgent Genetics, down from $369.3 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $602.2 million in Q3 2024 to a low of $326.6 million in Q4 2022.
• The 5-year median for Long-Term Investments is $415.6 million (2022), against an average of $439.5 million.
• Across the five-year window, Long-Term Investments jumped 71.47% in 2022 and sank 35.26% in 2025, its largest moves.
• Fulgent Genetics' Long-Term Investments stood at $326.6 million in 2022, then gained by 29.67% to $423.6 million in 2023, then surged by 34.65% to $570.4 million in 2024, then tumbled by 35.26% to $369.3 million in 2025, then decreased by 11.1% to $328.3 million in 2026.
• The last three Long-Term Investments figures came in at $328.3 million (Q1 2026), $369.3 million (Q4 2025), and $411.8 million (Q3 2025), per Business Quant data.